181 related articles for article (PubMed ID: 25599166)
1. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients.
Kamber C; Zimmerli S; Suter-Riniker F; Mueller BU; Taleghani BM; Betticher D; Zander T; Pabst T
Bone Marrow Transplant; 2015 Apr; 50(4):573-8. PubMed ID: 25599166
[TBL] [Abstract][Full Text] [Related]
2. A Japanese single-hospital observational trial with a retrospective case-control analysis of varicella zoster virus reactivation after autologous peripheral blood stem cell transplantation.
Mawatari M; Isoda A; Miyazawa Y; Sawamura M; Matsumoto M
Transpl Infect Dis; 2015 Aug; 17(4):544-50. PubMed ID: 26041667
[TBL] [Abstract][Full Text] [Related]
3. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Kohlmann R; Salmen A; Chan A; Knabbe C; Diekmann J; Brockmeyer N; Skaletz-Rorowski A; Michalik C; Gold R; Überla K
Mult Scler; 2015 Dec; 21(14):1823-32. PubMed ID: 25828755
[TBL] [Abstract][Full Text] [Related]
4. Serology indicates cytomegalovirus infection is associated with varicella-zoster virus reactivation.
Ogunjimi B; Theeten H; Hens N; Beutels P
J Med Virol; 2014 May; 86(5):812-9. PubMed ID: 24037981
[TBL] [Abstract][Full Text] [Related]
5. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.
Onozawa M; Hashino S; Takahata M; Fujisawa F; Kawamura T; Nakagawa M; Kahata K; Kondo T; Ota S; Tanaka J; Imamura M; Asaka M
J Clin Microbiol; 2006 Dec; 44(12):4441-3. PubMed ID: 17035500
[TBL] [Abstract][Full Text] [Related]
6. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation.
Yamazaki R; Nakasone H; Tanaka Y; Sato M; Terasako K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Machishima T; Kimura S; Kikuchi M; Okuda S; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1013-20. PubMed ID: 23583826
[TBL] [Abstract][Full Text] [Related]
7. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
[TBL] [Abstract][Full Text] [Related]
8. Disseminated zoster in an adult patient with extensive burns: a case report.
Kubota Y; Kosaka K; Hokazono T; Yamaji Y; Tezuka T; Akita S; Kuriyama M; Mitsukawa N
Virol J; 2019 May; 16(1):68. PubMed ID: 31122255
[TBL] [Abstract][Full Text] [Related]
9. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
Pour L; Adam Z; Buresova L; Krejci M; Krivanova A; Sandecka V; Zahradova L; Buchler T; Vorlicek J; Hajek R
Clin Lymphoma Myeloma; 2009 Apr; 9(2):151-3. PubMed ID: 19406726
[TBL] [Abstract][Full Text] [Related]
10. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
11. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
[TBL] [Abstract][Full Text] [Related]
12. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster prophylaxis with low-dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation.
Abbasov E; Metzner B; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voß A; Köhne CH
Eur J Haematol; 2022 Sep; 109(3):298-304. PubMed ID: 35687019
[TBL] [Abstract][Full Text] [Related]
14. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population.
Rogers JE; Cumpston A; Newton M; Craig M
Transpl Infect Dis; 2011 Oct; 13(5):480-4. PubMed ID: 21615848
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation.
Kalpoe JS; Kroes AC; Verkerk S; Claas EC; Barge RM; Beersma MF
Bone Marrow Transplant; 2006 Jul; 38(1):41-6. PubMed ID: 16715108
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of varicella-zoster virus reactivation in herpes simplex virus-seronegative patients with acute peripheral facial palsy.
Furuta Y; Ohtani F; Kawabata H; Fukuda S; Bergström T
Clin Infect Dis; 2000 Mar; 30(3):529-33. PubMed ID: 10722439
[TBL] [Abstract][Full Text] [Related]
17. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
18. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
[TBL] [Abstract][Full Text] [Related]
19. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
